{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:54:47Z","timestamp":1789606487387,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jcyt.2022.03.013","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T09:22:19Z","timestamp":1653124939000},"page":"962-973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications"],"prefix":"10.1016","volume":"24","author":[{"given":"Jeffrey","family":"Teoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren F.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jcyt.2022.03.013_bib0001","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jcyt.2022.03.013_bib0002","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jcyt.2022.03.013_bib0003","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jcyt.2022.03.013_bib0004","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jcyt.2022.03.013_bib0005","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcyt.2022.03.013_bib0006","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"14","key":"10.1016\/j.jcyt.2022.03.013_bib0007","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcyt.2022.03.013_bib0008","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1097\/HS9.0000000000000018","article-title":"Chimeric antigen receptor-T cell therapy: practical considerations for implementation in Europe","volume":"2","author":"Buechner","year":"2018","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.jcyt.2022.03.013_bib0009","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/trf.15287","article-title":"Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics","volume":"59","author":"Elavia","year":"2019","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.jcyt.2022.03.013_bib0010","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.xphs.2020.12.015","article-title":"Addressing patient to patient variability for autologous CAR T therapies","volume":"110","author":"Jiang","year":"2021","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.jcyt.2022.03.013_bib0011","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.jcyt.2022.03.013_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000148","article-title":"Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients","volume":"8","author":"Itzhaki","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.jcyt.2022.03.013_bib0013","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.jcyt.2022.03.013_bib0014","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: more than ease of access?","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"issue":"26","key":"10.1016\/j.jcyt.2022.03.013_bib0015","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2022.03.013_bib0016","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jcyt.2022.03.013_bib0017","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.jcyt.2022.03.013_bib0018","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"issue":"355","key":"10.1016\/j.jcyt.2022.03.013_bib0019","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"116","key":"10.1016\/j.jcyt.2022.03.013_bib0020","article-title":"Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study)","volume":"5","author":"DeAngelo","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"suppl 1","key":"10.1016\/j.jcyt.2022.03.013_bib0021","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2021-148792","article-title":"Outreach: results from a phase 2 study of lisocabtagene maraleucel (liso-cel) administered as inpatient (inpt) or outpatient (outpt) treatment in the nonuniversity setting in patients (pts) with R\/R large B-cell lymphoma (LBCL)","volume":"138","author":"Godwin","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jcyt.2022.03.013_bib0022","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-140491","article-title":"Updated follow-up of patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of transcend CLL 004, including high-risk and ibrutinib-treated patients","volume":"136","author":"Siddiqi","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcyt.2022.03.013_bib0023","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jcyt.2022.03.013_bib0024","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jcyt.2022.03.013_bib0025","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jcyt.2022.03.013_bib0026","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ni969","article-title":"Similarities and differences in CD4+ and CD8+ effector and memory T cell generation","volume":"4","author":"Seder","year":"2003","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.jcyt.2022.03.013_bib0027","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.jcyt.2022.03.013_bib0028","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nbt.3525","article-title":"Quality cell therapy manufacturing by design","volume":"34","author":"Lipsitz","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/j.jcyt.2022.03.013_bib0029","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CJI.0000000000000307","article-title":"Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib","volume":"43","author":"Qin","year":"2020","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2022.03.013_bib0030","article-title":"Single-cell sequencing reveals \u03b1\u03b2 chain pairing shapes the T cell repertoire","author":"Grigaityte","year":"2017","journal-title":"BioRxiv"},{"issue":"1","key":"10.1016\/j.jcyt.2022.03.013_bib0031","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00277-003-0817-8","article-title":"Cryopreservation of mobilized blood stem cells at a higher cell concentration without the use of a programmed freezer","volume":"83","author":"Kawano","year":"2004","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.jcyt.2022.03.013_bib0032","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0014-4827(72)90303-5","article-title":"A two-factor hypothesis of freezing injury. Evidence from Chinese hamster tissue-culture cells","volume":"71","author":"Mazur","year":"1972","journal-title":"Exp Cell Res"},{"issue":"1-2","key":"10.1016\/j.jcyt.2022.03.013_bib0033","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0022-1759(00)00269-6","article-title":"A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use","volume":"245","author":"Feuerstein","year":"2000","journal-title":"J Immunol Methods"},{"issue":"9","key":"10.1016\/j.jcyt.2022.03.013_bib0034","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2022.03.013_bib0035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr Opin Biotechnol"},{"issue":"10","key":"10.1016\/j.jcyt.2022.03.013_bib0036","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324922006119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324922006119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:46:57Z","timestamp":1761443217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324922006119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1465324922006119"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2022.03.013","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2022.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}